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OBJECTIVE: The aim of this study was to report a single center experience of organ and tissue transplantation 
INTRODUCTION: This is the first report of organ and tissue transplantation at the Hospital das Clínicas of the University of Sao 
Paulo Medical School. 
METHODS: We collected data from each type of organ transplantation from 2002 to 2007. The data collected were patient char-
acteristics and actuarial survival Kaplan-Meier curves at 30 days, one year, and five years
RESULTS: There were a total of 3,321 transplants at our institution and the 5-year survival curve ranged from 53% to 88%.
CONCLUSION: This report shows that solid organ and tissue transplants are feasible within the institution and allow us to expect 
that the quality of transplantation will improve in the future.
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INTRODUCTION
Transplantation has been an option for patients with 
end-stage organ disease and can provide a chance for 
survival. Our institution is one of the largest medical school 
hospitals in this country, with a relatively significant activity 
in complex procedures and transplants.1-5 The aim of this 
registry was to report the experience of transplantation at our 
institution for the last five years. It represents a unique data 
repository in an effort to help patients with untreated disease 
with conventional therapy. 
PATIENTS AND METHODS
Data were collected from each organ and tissue 
transplantation carried out from 2002 to 2007. The following 
parameters were studied: the number of transplants, age 
of recipient, indications for transplantation, maintenance 
immunosuppression protocols [calcineurin inhibitor 
(cyclosporine or tacrolimus), cytostatic drugs, and the use 
of steroids], major complications, causes of death, and the 
survival curve for each organ and tissue. 
For statistical analysis, all data were reported as median, 
minimum, and maximum values. Survival rates were 
calculated using the Kaplan-Meier method. All analyses 
were performed with SPSS statistical software, version 10.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
The registry of transplantation at the Hospital das 
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Clínicas of the University of Sao Paulo Medical School 
covers organ and tissue transplants from 2002 through 
2007.
The total number of recipients who received transplants 
was 3,321 (Table 1). There were 1,288 and 2,033 transplants 
of solid organs and tissue, respectively (Figure 1). The age 
of the recipients ranged from 0.6 to 90 years (Table 2). The 
distribution of the solid organ transplants per year ranged 
from 187 to 265 transplants (Figure 1). 
Pediatric heart transplantation
Thirty-two pediatric patients aged from 0.9 years to 
13.8 years (median: 6.0 years) were submitted to heart 
transplantation. The indications of heart transplantation were 
dilated cardiomyopathy in 25 patients (78%) and congenital 
heart disease in seven patients (22%). 
The immunosuppression used for induction therapy was 
methylprednisolone and thymoglobulin in all patients. The 
maintenance immunosuppression was the administration of 
calcineurin inhibitor in all patients, azathioprine in 4 patients 
(13%), and mychophenolate in 21 patients (65%). The major 
complications were 68 episodes of rejection (2.1 episodes 
per patient) and 61 episodes of infection (1.9 episodes per 
patient). No cases of tumor, diabetes mellitus, graft vascular 
disease, or renal failure (dialysis) were observed. Thirteen 
patients (40%) developed systemic arterial hypertension. 
Two re-transplantations were carried out. Nine (28%) 
patients died. The causes of mortality were rejection in five 
patients (55%), infection in three (33%), and multiple organ 
failure in one (11%) (Figure 2). The Kaplan-Meier curve 
was 80% at 30 days, 70% at 1 year, and 70% at 5 years 
(Figure 3).
Adult Heart Transplantation
There were a total of 109 adult patients who were 
submitted to heart transplantation. The median age of 
recipients was 47 years. The median age of donors was 31 
years. The immunosuppression for induction therapy was 
methylprednisolone in 103 patients (94.4%), mycophenolate 
in 58 patients (53.2%), azathioprine in 41 patients (37.6%), 
basiliximab in six patients (5.5%), and other drugs in seven 
(6.4%) patients. The maintenance immunosuppression 
protocol consisted of calcineurin inhibitor in 71 patients 
(96%), azathioprine in 28 (37.8%), mychophenolate in 42 
(56.8%), and steroids in 54 (73%). There were 43 (39.4%) 
deaths. The causes of mortality were graft failure in 11 
patients (26%), multiple organ failure in 10 (24%), infection Figure 1 - The total number of solid organ and tissue transplants per year (2002 to 2007)
Table 2 - Age distribution (years) of transplant recipients
Organ Median min max
Heart 
        Pediatric 6 0.9 13.8
        Adult 47  11 69
Liver
        Pediatric 4 0.6 16
        Adult 47 14 70
Pancreas-kidney 36 25 41
Lung 47 6 67
Kidney
        Pediatric 13 3 17
        Adult 45 18 78
Table 1 - Number of transplant recipients at Hospital das 
Clínicas of the University of São Paulo Medical School 
(2002-2007)
Organ N
Heart 
 - Pediatric 32
 - Adult 109
Liver
 - Pediatric 135
 - Adult 204
Pancreas-kidney 37
Lung 56
Kidney 715
 - Adult 665
 - Pediatric 50
Total 1288
Tissue N
Bone marrow
 - Pediatric 57
 - Adult 728
Skin 81
Bone 1167
Total 2033
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Figure 2 - Causes of mortality (2002 to 2007)
in seven (17%), rejection in six (14%), other causes in seven 
(17%), and an unknown cause in two (2%) (Figure 2). The 
Kaplan-Meier was 76% at 30 days, 64% at one year, and 
56% at five years (Figure 3). 
Adult liver transplantation
Two hundred and four patients received 225 liver 
transplants (21 were re-transplants). The median age 
of recipients was 47 years (range, 14 to 70 years). The 
indications for liver transplantation are in table 3. Patients 
received immunosuppression with tacrolimus in 195 cases 
(96%) or cyclosporine in 9 (4%) and steroids, azathioprine 
in 6 (3%) or mycophenolate in 32 (16%). There were 71 
deaths. The causes of mortality were infection in 25 patients 
(35%), primary graft dysfunction in 17 (24%), neurologic 
complication in six (8.5%), hepatitis C virus reinfection 
in 3 (4.2%), and other causes in 20 (28%) (Figure 2). The 
Kaplan-Meier overall survival was 83.8% at 30 days, 70.2% 
at one year, and 66.9% at five years (Figure 3).
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Figure 3 - Kaplan Meier survival curves - (2002 to 2007)
Pediatric liver transplantation
One hundred thirty five patients received liver transplants. 
The median age of recipients was 4 years (range, 7 months 
to 16 years). The indications for liver transplantation were 
biliary atresia in 75 patients (55%), alpha-1 antitrypsin 
deficiency in five (4%), fulminant hepatitis insufficiency in 
13 (10%), and other indications in 42 (31%). The induction 
therapy was tacrolimus and steroids in 96 (71.1%) patients, 
cyclosporine and steroids in 20 (14.8%), and other drugs 
in 19 (14.1%). The maintenance immunosuppression was 
tacrolimus in 69 patients (80.2%), mycophenolate in 23 
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(26.7%), steroids in 64 (74.4%), and other treatments in 9 
(10.4%). There were 49 deaths. The causes of mortality were 
septicemia in nine patients (19%), thrombosis in nine (19%), 
primary graft failure in eight (16%), fulminant hepatic 
insufficiency in seven (14%), chronic rejection in seven 
(14%), post-transplantation lymphoproliferative disease in 
three (6%), and other causes in four (12%) (Figure 2). The 
Kaplan-Meier survival curve was 84.4% at 30 days, 64.5 % 
at one year, and 61.8 % at five years (Figure 3).
Lung transplantation
Fifty-six patients received lung transplants. The median 
age was 47 years (range, 6 years to 67 years). There was only 
one child (six years old) in this group. The indications were: 
chronic obstructive pulmonary disease in 15 patients (27%), 
fibrosis in 15 (27%), bronchiectasis in 13 (23%), cystic 
fibrosis in eight (14%), and other indications in five (9%). 
The immunosuppression for induction therapy involved 
methylprednisolone in 56 patients (100%), basiliximab in 
20 patients (36%), anti-thymocyte globulin in two (4%), 
and no other induction in 34 (58%). Immunosuppression 
was maintained using calcineurin inhibitor in 56 patients 
(100%), azathioprine in 25 (45%), mycophenolate in 27 
(48%), and steroids in 56 (100%). There were 22 deaths. 
The causes of mortality were infection in 11 patients (52%), 
primary graft failure in four (18%), surgical complications 
in four (18%) patients (empyema, anastomosis dehiscence 
in two (8%), and one patient (4%) for each of the following 
conditions: hemoptysis and bronchovascular fistula 
and hemorrhage), right ventricular failure in one (4%), 
pulmonary thromboembolism in one (4%), and unknown 
cause in one (4%) (Figure 2). The Kaplan-Meier survival 
curve was 77.7% at 30 days, 70.0% at one year, and 53.3% 
at five years (Figure 3).
Simultaneous pancreas-kidney transplantation
Thirty-seven patients received pancreas kidney 
transplants. The median age of recipients was 36 years 
(range, 25 years to 51 years). The indications were type I 
diabetes with renal chronic failure in 32 (86.5%) patients, 
type I diabetes following kidney transplantation in three 
(8.1%) patients, and type I diabetes in two (5.4%) patients. 
The immunosuppression for induction therapy was: IL2R 
(daclizumab), tacrolimus, mycophenolate and steroids in 
16 patients (43%); and anti-thymocyte horse globulin – 
thymoglobulin, tacrolimus, mycophenolate, and steroids 
in 21 (56.7%). The maintenance immunosuppression in 
all patients was tacrolimus, mycophenolate, and steroids. 
There were seven deaths. The causes of mortality were 
cardiovascular complications in four patients (57%), septic 
shock in two (29%), and tumor in one (14%) (Figure 2). The 
Kaplan-Meier overall recipient survival curve was 97.3% 
at 30 days, 84.9% at one year, and 74.2% at five years. The 
pancreatic graft survival curve was 97.3% at 30 days, 79.4% 
at one year, and 56.7% at five years; kidney graft survival 
was 97.3% at 30 days, 84.5% at one year, and 73.9% at five 
years (Figure 3).
Kidney transplantation
A total of 715 patients aged from 3 to 78 years (median, 
41.3 years) were submitted to kidney transplantation. The 
indications for pediatric and adult kidney transplantation 
are given in Tables 4 and 5, respectively. The most common 
indication was chronic glomerulonephritis in 140 patients 
(21%). 
Pediatric kidney transplantation: 50 children received 
kidney transplants. The median age was 13 years (range, 
3 to 17 years). The immunosuppression used for induction 
therapy in children was basiliximab in 14 patients (28%), 
daclizumab in 28 (56%), and antithymocyte globulin in 
six (12%). The maintenance immunosuppression was 
tacrolimus, mychophenolate, and steroids in 45 patients 
(90%); and cyclosporine, mycophenolate, and steroids in five 
(10%). Four patients died. The causes of death for the four 
were acute edema, sudden death, infection, and an unknown 
cause (Figure 2). The Kaplan-Meier graft survival curve 
was 95.9% at 30 days, 88.7% at one year, and 76.7% at 
five years. The patient survival curve was 100% at 30 days, 
97.7% at one year, and 78.1% at five years (Figure 3).
Adult kidney transplantation: 665 adult patients were 
Table 3 - Indications for adult liver transplantation
Disease N %
Hepatitis C virus 42 18.7
Fulminant hepatitis 42 18.7
Hepatocarcinoma and cirrhosis 42 18.7
retransplantation 21 9.3
Autoimmune hepatitis 17 7.5
Hepatitis B virus 16 7.1
Cryptogenic
cirrhosis 13 5.7
Alcohol 12 5.3
Primary biliary cirrhosis 6 2.6
Primary sclerosant cholangitis 2 1.0
Others 12 5.3
Total 225 100
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submitted to kidney transplantation. The median age was 45 
years (range, 18 to 78 years). The induction therapy in adults 
was basiliximab in 306 (46%) patients, daclizumab in 162 
(24.3%), antithymocyte globulin in 96 (14.4%), and OKT3 
in 10 (1.5%) patients. The maintenance immunosuppression 
was tacrolimus, mychophenolate, and steroids in 497 
patients (74.8%); cyclosporine, mycophenolate, and steroids 
in 84 (12.7%); cyclosporine, azathioprine and steroids in 20 
(3%); cyclosporine, rapamycin, and steroids in 16 (2.4%); 
and other therapy in 48 (7.1%). Eighty patients died. The 
causes of mortality were septic shock in 44 patients (55%), 
myocardial infarction in five (6%), sudden death in four 
(5%), shock in eight (10%), unknown causes in four (5%), 
and other causes in 15 (19%) (Figure 2). The Kaplan-Meier 
graft survival curve was 92.9% at 30 days, 83.2% at one 
year, and 70.1% at five years (Figure 3). The patient survival 
curve was 96.6% at 30 days, 91.0% at one year, and 83.2% 
at five years (Figure 3).
Pediatric bone marrow transplantation
Thirty-four patients received autologous bone marrow 
transplants. The median age of recipients was 6.6 years. 
The indications were the following: neuroblastoma in 25 
patients, Ewing sarcoma in three, non-Hodgkin lymphoma 
in three, meduloblastoma in two, and Wilms’ tumor in 
one. The immunosuppression for induction therapy was 
carboplatin (CBDCA), etoposide (ETO), and melphalan 
(MELFA) in 29 patients; bleomycin, etoposide, cytarabine, 
and melphalan (BEAM) in two; CBDCA/ETO in three; and 
cisplatin (CDDP), cyclophosphamide (CTX), and vincristine 
(VCR) in two. The number of deaths was seven. The causes 
of mortality were tumor in six patients (86%) and septic 
shock in one (Figure 2). The Kaplan-Meier survival curve 
was at 96.8% at 30 days, 93.1% at one year, and 67% at five 
years (Figure 3). 
Five children with acute myeloid leukemia (AML) and 18 
children with acute lymphocytic leukemia (ALL) underwent 
to allogeneic bone marrow transplantation. 
Adult bone marrow transplantation
A total of 728 patients underwent hematopoietic stem 
cell transplantation (HSCT). The indications for HSCT were 
multiple myeloma (173), non-Hodgkin lymphoma (169), 
acute myeloid leukemia (101), Hodgkin lymphoma (109), 
chronic myeloid leukemia (81), severe aplastic anemia (55), 
and acute lymphocytic leukemia (40). The indications are 
listed in Table 6. 
The following conditioning regimens were used for the 
different diseases:
-  non-Hodgkin lymphoma patients: BEAM – BCNU 
(carmustine) 300 mg/m2 + etoposide (800 mg/ m2) + 
cytarabine (1600 mg/ m2) + melphalan (140 mg/ m2);
-  multiple myeloma patients: busulfan (12 mg/kg) + 
melphalan (100 mg/ m2) for autologous transplantation; 
fludarabine (125 mg/ m2) + melphalan (180 mg/ m2) for 
allogeneic transplantation;
-  Hodgkin lymphoma patients: MBV – melphalan (140 
mg/ m2) + BCNU (carmustine; 300 mg/ m2) + VP-16 
(etoposide; 2000 mg/ m2);
-  acute myeloid leukemia patients and chronic myeloid 
leukemia patients: busulfan (16 mg/kg) + melphalan (140 
mg/ m2);
-  severe aplastic anemia patients: busulfan (4 mg/kg) + 
cyclophosphamide (200 mg/kg), or total body irradiation 
(300 rads) + cyclophosphamide (200 mg/kg);
-  acute lymphocytic leukemia patients: busulfan (16 mg/
kg) + melphalan (140 mg/ m2), or total body irradiation 
(1200 rads) + cyclophosphamide (120 mg/kg);
Table 5 - Indications for adult kidney transplantation
Disease N %
Chronic glomerulonephritis 140 21
Systemic arterial hypertension 104 15.6
Diabetes mellitus 90 13.5
Unknown renal insufficiency 75 11.3
Polycystic kidney disease 24 3.6
Nephrotic syndrome 20 3
Chronic Obstructive pyelonephritis 18 2.7
Lupic nephritis 16 2.4
Focal segmental glomerular sclerosis 7 1.0
Others 171 25.9
Total 665 100
Table 4 - Indications for pediatric kidney transplantation
Disease N %
Chronic obstructive pyelonephritis 10 20
Nephrotic syndrome 8 16
Chronic  glomerulonephritis 8 16
Hemolytic uremic syndrome 4 8
Renal hypoplasia 3 6
Unknown renal insufficiency 3 6
Focal segmental glomerular sclerosis 2 4
Congenital defect 2 4
Reflux nephropathy 2 4
Others 8 16
Total 50 100
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The maintenance immunosuppression after allogeneic 
transplantation was cyclosporine A at a dose of 3 mg/kg/day 
(intravenous infusion), together with methotrexate at a dose 
of 15 mg/m2) on day +1 and a dose of 10 mg/ m2 on days +3, 
+6, and, +11 after HSCT.
Bone transplantation
A total of 1167 patients received bone, ligament, 
or tendon transplants. The median age of recipients 
was 48 years (range, 2 to 90 years). The indications for 
transplantation were either odontologic (813 patients, 
69.7%) or orthopedic (354 patients, 30.3%). Odontological 
indications of bone transplantation were mandibular and 
maxilar bone loss caused by tumors, trauma, and periodontal 
disease. Orthopedic indications were divided into the 
following groups: hip surgery (177, 50%), knee surgery 
(128, 36%), tumor surgery (35, 10%), and shoulder surgery 
(14, 4%). The main indication for hip surgery was revision 
hip arthoplasty with femoral or acetabular bone loss. Bone 
and ligament transplantation in knee surgery was used in 
revision knee arthoplasty, reconstruction of anterior cruciate 
ligament injury, (patellar graft, semitendinosus and gracilis 
graft), and severe trauma. The indications for the tumor 
group were benign lesions (unicameral and aneurismal 
bone cysts, non-osteogenic fibromas), and malignant 
tumors (Ewing sarcoma and osteosarcoma). Indications 
for shoulder surgery were repair of rotator cuff injuries and 
acromioclavicular dislocations using ligaments and rotator 
cuff grafts. Immunosuppression was not used for induction 
or maintenance therapy, since bone, ligament, and tendon 
transplantation, unlike transplantation of other solid organs, 
do not cause death in the event of graft failure. The main 
complications of bone transplantation were infection and 
immunogenic reaction against the graft. Of 35 patients in the 
tumor group, two (5.7%) developed infection, two (5.7%) 
had immunogenic reactions, three (8.6%) had allograft 
fractures that required revision and autologous bone grafts, 
and one (2.9%) had recurrence of the tumor in the leg that 
had received the transplantation, and the leg was therefore 
amputated.
Skin transplantation
Eighty-one patients aged 0.3 years to 78 years (median, 
34 years) received skin transplants. The main use of this 
transplantation was for temporary skin coverage until an 
autogenous graft could be implanted. The indications for 
skin transplantation were large burns with few skin donor 
areas in 38 patients (46.9%), wound bed preparation in 
28 (34.5%), hemodynamic instability in seven (8.6%), 
pyoderma gangrenosum in four (4.9%), aplasia cutis in two 
(2.4%), and giant congenital nevi in two (2.4%). After 3-5 
days, the allogeneic skin was removed and the wound bed 
was evaluated. If there was sufficient granulation tissue then 
an autogenous graft was made; if the granulation tissue was 
not good, a new transplantation was performed. In this way, 
22 patients received a re-transplantation for wound bed 
preparation. The mortality rate of the patients was 16.4%: 13 
patients died, five in the group of hemodynamic instability 
and eight in the group of large burns with few donor skin 
sites. 
COMMENTS AND DISCUSSION
The total number of solid organ transplant procedures 
(38.7%) of all transplants remained unchanged during 
the period (range, 2002 to 2007). The number of tissue 
transplants increased during the last two years, especially 
bone transplants. 
Immunosuppression: The most common combinations of 
therapies included calcineurin inhibitor and mycophenolate. 
A smaller percent of patients were taking a calcineurin 
inhibitor combined with azathioprine. 
Outcomes: Overall survival at 30 days, one year, and 
five years shows that the results of our institution6-21 are 
compatible with previously reported data.22-26 Infection and 
rejection were the main causes of death in the majority of the 
organ transplants in our report. This indicates that these two 
complications remain a challenge for physicians who take 
care of organ transplant patients. 
We will continue to update our experience in an 
attempt to describe what is presently occurring in organ 
transplantation in our institution. 
CONCLUSION
This is the initial registry report from our institution. It 
Table 6 - Indications for adult hematopoietic stem cell 
transplantation 
Disease N %
Multiple Myeloma 173 23.8
Non-Hodgkin Lymphoma 169 23.2
Hodgkin Lymphoma 109 14.9
Acute Myeloid Leukemia 101 13.9
Chronic Myeloid Leukemia 81 11.1
Severe Aplastic Anemia 55 7.5
Acute Lymphocytic Leukemia 40 5.6
Total 728 100
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will help us define baseline data that will form the basis of 
comparison for our future reports. This report shows that 
solid organ and tissue transplantations are feasible within 
the institution and they allow us to expect that the quality of 
results will improve in the future.
APPENDIx
The members of the Solid Organ and Tissue 
Transplantation Committee of Hospital das Clínicas of 
University of São Paulo Medical School were as follows: 
Estela Azeka, José Otavio Costa Auler Júnior, Paulo Manuel 
Pego Fernandes, Willian Carlos Nahas, Alfredo Inácio 
Fiorelli, Uenis Tannuri, Lílian Maria Cristofani, Marcelo 
Tadeu Caiero, Frederico Luiz Dulley, André de Oliveira 
Paggiaro, Telesforo Bacchella. José Otavio Costa Auler Jr. 
was also the clinical director of the Hospital das Clínicas of 
University of São Paulo Medical School.
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